Title: Comparative Real-world Outcomes between Ustekinumab, Infliximab, and Adalimumab
in Bio-naïve and Bio-experienced Crohn’s Disease Patients: A Retrospective Multicenter Study
Version: 1 Date: 12 Mar 2024
Reviewer's report:
This study investigated the effectiveness of UST, IFX, and ADA for treating Crohn's disease,
with a focus on their efficacy for bio-naive and bio-failure patients.
Comment 1:
The description of the evaluation method for propensity score matching is insufficient. It is
necessary to describe the specific matching method, covariates used for matching, and caliper
values used. Please add this information to the Method section.
Comment 2 :
In the Discussion section, the statement 'We could not compare efficacy based on the reasons for
discontinuing previous biologics' is a reasonable opinion. However, in Table 3, which presents
the baseline characteristics of bio-experienced Crohn's disease patients, details of past use of
each biologic product are required for both the UST group and the Anti-TNF agents group.
Additionally, it is important to consider that subsequent maintenance of remission may differ
depending on why the biologic was changed. For instance, it may introduce bias to not disclose
whether the change was due to surgery or if a lesion that is resistant to medical treatment has
developed. Additionally, since the UST group has a natural proficiency in using bio-preparations
compared to the anti-TNF agents group, it is possible that they make better treatment choices.
This limitation should be added in the Discussion section.
Comment 3:
In certain countries, it may be possible to shorten the duration or double the dose of IFX, ADA,
and UST. The Method section provides general dosages of those biologics, but it is important
to state in the Results section whether they were followed in all cases. If there are any relevant
cases, they should be described in the Results section.
Comment 4:
Please ensure that there are no spelling mistakes.
Ex) Immunomodulators
Title: Comparative Real-world Outcomes between Ustekinumab, Infliximab, and Adalimumab
in Bio-naïve and Bio-experienced Crohn’s Disease Patients: A Retrospective Multicenter Study
Version: 1 Date: 12 Mar 2024
Reviewer's report:
This study investigated the effectiveness of UST, IFX, and ADA for treating Crohn's disease,
with a focus on their efficacy for bio-naive and bio-failure patients.
Comment 1:
The description of the evaluation method for propensity score matching is insufficient. It is
necessary to describe the specific matching method, covariates used for matching, and caliper
values used. Please add this information to the Method section.
Comment 2 :
In the Discussion section, the statement 'We could not compare efficacy based on the reasons for
discontinuing previous biologics' is a reasonable opinion. However, in Table 3, which presents
the baseline characteristics of bio-experienced Crohn's disease patients, details of past use of
each biologic product are required for both the UST group and the Anti-TNF agents group.
Additionally, it is important to consider that subsequent maintenance of remission may differ
depending on why the biologic was changed. For instance, it may introduce bias to not disclose
whether the change was due to surgery or if a lesion that is resistant to medical treatment has
developed. Additionally, since the UST group has a natural proficiency in using bio-preparations
compared to the anti-TNF agents group, it is possible that they make better treatment choices.
This limitation should be added in the Discussion section.
Comment 3:
In certain countries, it may be possible to shorten the duration or double the dose of IFX, ADA,
and UST. The Method section provides general dosages of those biologics, but it is important
to state in the Results section whether they were followed in all cases. If there are any relevant
cases, they should be described in the Results section.
Comment 4:
Please ensure that there are no spelling mistakes.
Ex) Immunomodulators
Please review this paper.
user
Title: Comparative Real-world Outcomes between Ustekinumab, Infliximab, and Adalimumab
in Bio-naïve and Bio-experienced Crohn’s Disease Patients: A Retrospective Multicenter Study
Version: 1 Date: 12 Mar 2024
Reviewer's report:
This study investigated the effectiveness of UST, IFX, and ADA for treating Crohn's disease,
with a focus on their efficacy for bio-naive and bio-failure patients.
Comment 1:
The description of the evaluation method for propensity score matching is insufficient. It is
necessary to describe the specific matching method, covariates used for matching, and caliper
values used. Please add this information to the Method section.
Comment 2 :
In the Discussion section, the statement 'We could not compare efficacy based on the reasons for
discontinuing previous biologics' is a reasonable opinion. However, in Table 3, which presents
the baseline characteristics of bio-experienced Crohn's disease patients, details of past use of
each biologic product are required for both the UST group and the Anti-TNF agents group.
Additionally, it is important to consider that subsequent maintenance of remission may differ
depending on why the biologic was changed. For instance, it may introduce bias to not disclose
whether the change was due to surgery or if a lesion that is resistant to medical treatment has
developed. Additionally, since the UST group has a natural proficiency in using bio-preparations
compared to the anti-TNF agents group, it is possible that they make better treatment choices.
This limitation should be added in the Discussion section.
Comment 3:
In certain countries, it may be possible to shorten the duration or double the dose of IFX, ADA,
and UST. The Method section provides general dosages of those biologics, but it is important
to state in the Results section whether they were followed in all cases. If there are any relevant
cases, they should be described in the Results section.
Comment 4:
Please ensure that there are no spelling mistakes.
Ex) Immunomodulators
assistant